Abstract
Objective This study aimed to detect which of the two main medicines suggested in the treatment
of postligation cardiac syndrome (PLCS)—dobutamine or mirinone—possesses a more therapeutic
effect. While doing this, clinicians are provided with a broader perspective on the
treatment and follow-up of cases. The desire was to increase the treatability and
monitor ability of the cases in question and hence their survivability.
Study Design A retrospective review of a cohort of infants with PLCS was conducted between March
2012 and December 2018. In the treatment of infants with PLCS, dobutamine (dobutamine
study group-DSG) or milrinone (milrinone study group-MSG) was used. The respiration,
cardiac, echocardiography, and perfusion parameters of the cases were assessed both
before and after ligation. Based on the data obtained, both the effects of the medicines
on PLCS and the difference between their therapeutic effects were studied. The accuracy
of prognostication was assessed with receiver operating characteristic analyses.
Results PLCS was detected in 29 (34.1%) of 85 patent ductus arteriosus ligation cases in
total. Of all the PLCS cases, 13 (44.8%) were treated with dobutamine and 16 (55.2%)
with milrinone. It was observed that the effects of the medicines on the respiratory
system and cardiovascular system manifested in the third and 6th hour, respectively.
It was detected that both medicines had more effect on the systolic blood pressure
(SBP) (area under the curve [AUC]: 0.997/0.996, p = 0.001/0.002) than on the diastolic blood pressure (AUC: 0.911/0.843, p = 0.032/0.046).
Conclusion Dobutamine and milrinone, two primary medicines that can be used in the treatment
of cases with PLCS, possess similar therapeutic effects on this pathology. In addition,
their postoperative therapeutic effects on the SBP are more in the foreground.
Keywords
patent ductus arteriosus - postligation cardiac syndrome - preterm infants - dobutamine
- milrinone
